Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia

Share this content:
Patients with chronic myelomonocytic leukemia may experience a good response with decitabine.
Patients with chronic myelomonocytic leukemia may experience a good response with decitabine.

Patients with high-risk chronic myelomonocytic leukemia (CMML) may experience prolonged overall survival (OS) and increased overall response rate (ORR) from treatment with decitabine, according to a study published in Leukemia.

CMML is a highly complex clonal hematologic disorder that does not have many effective therapeutic options, and management is usually based in supportive care and cytoreductive therapy. CMML is classified among myelodysplastic (MDS)/myeloproliferative neoplasms. Evidence from previous studies suggests that patients with CMML may experience a good response with decitabine.

This phase 2 study (ClinicalTrials.gov Identifier: NCT01251627) enrolled 43 patients with CMML to receive decitabine 20 mg/m2 on days 1 to 5 of a 28-day cycle. More than 50% of study patients were considered to be high risk. Follow-up was performed at the end of treatment cycles 4 and 6, and patients who responded to treatment at the end of 6 cycles would continue treatment.

After a median duration of 51.5 months, the median OS was significantly longer at 17.0 months compared with patients who did not receive decitabine (P =.02).

After 6 cycles of treatment, the ORR was 47.6%. Nineteen percent of patients had marrow responses, 16.6% of patients had complete responses, 9.5% of patients demonstrated hematologic improvements, and 2.4% of patients had a partial response.

The most frequently reported grade 3 or 4 adverse events were thrombocytopenia, anemia, and neutropenia, occurring in 38%, 28.6%, and 50% of patients, respectively.

The authors of the study concluded that “decitabine appears to be an effective treatment for patients with high-risk CMML, including those with proliferative disease. Further research is needed to determine whether there is a difference in response between low- and high-risk patients.”

Reference

1. Santini V, Allione B, Zini G, et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia [published online July 7, 2017]. Leukemia. doi: 10.1038/leu.2017.186

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs